课题基金 / 基金详情

HIV-1 REV PROTEIN--BIOCHEMICAL MECHANISMS

HIV-1 REV PROTEIN--BIOCHEMICAL MECHANISMS
HIV-1 REV 蛋白--生化机制
批准号:
2672095
负责人:
MICHAEL R GREEN
金额:
$25.7万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-07-01 至 2000-05-31

项目摘要

项目成果

MICHAEL R GREEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: HIV-1 Rev protein is required for viral replication and acts by facilitating this cytoplasmic accumulation of incompletely-spliced viral mRNA that encodes structural proteins. Rev is a sequence-specific RNA binding protein which interacts with the viral RNA element designated RRE. The two long-term objectives of this application are to: 1) Understand how Rev facilitates viral mRNA transport and 2) to develop small molecules and protein-based Rev inhibitors. Over the previous period of funding, a significant advance has been the cloning of a human Rev cofactor (hRIP) which is a major focus of this application. The investigator proposes to study in greater detail how Rev and hRIP collaborate to facilitate export of HIV-1 RNAs. The process of cellular mRNA nuclear export is poorly understood and this will be a major portion of the application. The second major objective is to develop Rev inhibitors. This laboratory has demonstrated certain small molecules, such as specific aminoglycoside antibiotics, which interact with the RRE to inhibit Rev binding and Rev function. Further studies on these small molecular RNA interactions will be evaluated in this application. Finally, the investigator has recently discovered methodologies to select artificial peptides to specifically interact with Rev within cells and may block Rev function. These studies will be extended and the development of more potent and specific Rev inhibitors is proposed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia
Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
海外基金